Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.

Eli Lilly LLY 0.62% agreed to acquire Verve Therapeutics VERV -0.27% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

Eli Lilly's (LLY) $1.3B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both companies.

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment. Read more on my thoughts on this deal.

Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering better commercial prospects.

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio.

Eli Lilly (NYSE:LLY) has agreed to acquire Boston-based gene editing startup Verve Therapeutics (NASDAQ:VERV) for up to $1.3B. Pursuant to the agreement, Lilly will commence a tender offer to ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies.

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.